Formulation design and pharmaceutical evaluation of an HFA 227-based furosemide metered dose inhaler

Journal of Drug Delivery Science and Technology

Volumn 14, Issue 2, 2004, Pages 135-140

  Saso, Y ^a   Kondo, S ^a   Seki, T ^b   Morimoto, K ^b  

^a Aventis Pharma Ltd   (Japan)

^b HOKKAIDO INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

Cosolvent; Furosemide; Heptafluoroalkanepropane; Metered dose inhaler; Non CFC propellant; Surfactant

Indexed keywords

ALCOHOL; ALUMINUM; APAFLURANE; CHLOROFLUOROCARBON; FUROSEMIDE; MACROGOL; OLEIC ACID; PROPELLANT; SOLVENT; SURFACTANT;

ADDITION REACTION; ARTICLE; ASTHMA; CHEMICAL MODEL; CONCENTRATION (PARAMETERS); CONTAINER; DEVICE; DOSE CALCULATION; DRUG DESIGN; DRUG EFFECT; DRUG FORMULATION; DRUG RESEARCH; DRY DEPOSITION; HUMAN; IN VITRO STUDY; METERED DOSE INHALER; PARTICLE SIZE; SEDIMENTATION; SUSPENSION; TAIL OFF PHENOMENON;

EID: 1942537630     PISSN: 11571489     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1773-2247(04)50025-4     Document Type: Article

References (19)

1. ATKINS P. J., BARKAR N. P., MATHISEN D. - The design and development of inhalation drug delivery systems. - In: Pharmaceutical Inhalation Aerosol Technology, J. A. Hickey Ed., Marcel Dekker, New York, 1992, pp. 155-185.
2. VERVAET C., BYRON P. R. - Drug-surfactant-propellant interactions in HFA-formulation. - Int. J. Pharm., 186, 13-30, 1999.
3. LEACH C. L. - Approaches and challenges to use freon propellant replacements. - Aerosol Sci. Tech., 22, 328-334, 1995.
4. McNAMARA D. P., TURI J. S., VAN CAMPEN L. - Issues surrounding MDI formulation development with non-CFC propellants. - J. Aerosol Med., 4, 181-187, 1991.
5. AMITH I. J. - The challenge of reformulation. - J. Aerosol Med., 8, s19-s27, 1995.
6. BYRON P. R., BLONDINO F. - Pharmaceutically acceptable agents for solubilizing, wetting, emulsifying, or lubricating in metered dose inhalers formulations which use HFC-227 propellant. - US patent, 5,483,953, 1996.
7. BYRON P. R., BLONDINO F. - Metered dose inhalers formulations which include the ozone-friendly propellant HF-134A and a pharmaceutically acceptable suspending, solubilizing, wetting, emulsifying or lubricating agent. - US Patent, 5,492,688, 1996.
8. GONDA I. - Development of a systematic theory of suspension inhalation aerosols. I. A. framework to study the effects of aggregation on the aerodynamic behavior of drug particles. - Int. J. Pharm., 27, 99-116, 1985.
9. HICKEY A. J., DALBY R. N., BYRON P. R. - Effects of surfactants on aerosol powders in suspension. Implications for air born particle size. - Int. J. Pharm., 42, 267-270, 1988.
10. BYRON P. R. - Dosing reproducibility from experimental albuterol suspension metered-dose inhalers. - Pharm. Res., 1, 580-584, 1994.
11. BLANCO S., PIERONI M. G., REFINI R. M., ROTTOLI L., SESTINI P. - Protective effect of inhaled furosemide on allergen-induced early and late asthmatic reaction. - N. Eng. J. Med., 321, 1063-1073, 1989.
12. European Pharmacopoeia, Appendix XII F, 2002, A244.
13. POLLI G. P., GRIME W. M., BACHER F. A., YUNKER M. H. - Influence of formulation on aerosol particle size. - J. Pharm. Sci., 58, 484-486, 1969.
14. NEWMAN S. P., MOREN F., PAVIA D., CORRADO O., CLARKE S. W. - The effect of changes in metered volume and propellant vapor pressure on the deposition of pressurized inhalation aerosols. - Int. J. Pharm., 11, 337-344, 1982.
15. TANSEY I. P. - Changing to CFC-free inhalers: The technical and clinical challenges. - Pharmaceut. J., 259, 896-898, 1997.
16. TANSEY I. P. - The challenges in the development of metered dose inhalation aerosols using ozone-friendly propellants. - Spray Technol. Marketing, July, 26-29, 1994.
17. TANSEY I. P. - Technological development of Airomir (Salbutamol sulphate in CFC-Free system) MDI. - Br. J. Clin. Pract., 79, 13-15, 1995.
18. DEGER H.-M. - Medizinische aerosolformulierung. - EU Patent, 0550031A1, 1993.
19. BIANCO S. - Method for treating asthma. - US Patent, 4,908,382, 1990.